Page 84 - Quest Diagnostics News Today

Blood tests for Alzheimer's are needed to more widely diagnose the brain-wasting disease and understand its prevalence, but it will be another couple of years before they become an everyday tool, medical experts and company executives say. Blood testing is initially likely to be used to rule out Alzheimer's, with positive results signaling the need for more advanced diagnostics. Several Alzheimer's blood tests are in the works – and one is already being sold to consumers ...

Expanding Healthcare Access and Affordability at Quest Diagnostics

By Deena Beasley (Reuters) - Blood tests for Alzheimer's are needed to more widely diagnose the brain-wasting disease and understand its prevalence, b...

A number of blood tests for Alzheimer's are being developed, and one is even now being sold to consumers, but none have been proven to be reliable, formally approved by regulators, or paid for by insurance companies.

/PRNewswire/ -- AstronauTx Ltd. ("AstronauTx"), a biotech company developing novel treatments for Alzheimers disease and other neurodegenerative disorders,...

Manning & Napier Group LLC grew its position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 10.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 49,664 shares of the medical research company’s stock after acquiring an additional 4,863 shares during the quarter. Manning & […]

Quest Diagnostics (NYSE:DGX – Get Free Report) and RushNet (OTCMKTS:RSHN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends. Analyst Ratings This is a summary of recent ratings […]

The “Breast Cancer Screening Market 2023“ research report provides a comprehensive analysis of the competitive market landscape, focusing on key metrics such as production volume, profits, and sales. Additionally, the report delves into the intricacies of the supply chain analysis of leading industry players. The global breast cancer screening market size was US$ 5.1 billion […] | 2023-10-09 08:03:47

Cozad Asset Management Inc. lessened its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 1.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,033 shares of the medical research company’s stock after selling 246 shares during the quarter. […]

Palumbo Wealth Management LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 5,197 shares of the medical research company’s stock, valued at approximately $730,000. A number of other institutional investors have […]